Bimzelx 160 mg/mL
bimekizumab · INJECTION, SOLUTION · UCB, Inc.
No Recall History
Plain English
Bimzelx is a injection, solution containing bimekizumab at 160 mg/mL, taken subcutaneous. Manufactured by UCB, Inc..
Key Facts
- Brand Name
- Bimzelx
- Generic Name
- bimekizumab
- NDC Code (Product)
50474-781- Manufacturer
- UCB, Inc.
- Strength
- 160 mg/mL
- Dosage Form
- INJECTION, SOLUTION
- Route
- SUBCUTANEOUS
- Marketing Status
- Application #
- BLA761151
- Marketing Start
- 10/17/2023
Recall History
No Recall HistorySide Effects Reported to FDA
FDA FAERS database · These are reported events, not confirmed side effects
product dose omission issue2,604 reports
psoriasis2,019 reports
drug ineffective1,487 reports
psoriatic arthropathy1,391 reports
off label use1,202 reports
hidradenitis1,191 reports
injection site pain960 reports
condition aggravated911 reports
inappropriate schedule of product administration766 reports
therapy interrupted735 reports
Frequently Asked Questions
What is Bimzelx used for?
Bimzelx contains bimekizumab. It is a injection, solution taken subcutaneous. Consult your doctor for specific uses.
Is Bimzelx a controlled substance?
Bimzelx is not classified as a controlled substance by the DEA.
What is the generic name for Bimzelx?
The generic name for Bimzelx is bimekizumab. There are no other listed brand versions of bimekizumab.
What is the NDC code for Bimzelx 160 mg/mL?
The NDC (National Drug Code) for Bimzelx 160 mg/mL is 50474-781, listed by UCB, Inc..
Other Bimzelx Dosages
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)